Upfront
References
by
Ralph Valle

1. Cancer Facts & Figures 1999 -The American Cancer Society

2. Gilliland FD, et al. Male genital cancers. Cancer. 1995 Jan 1;75(1 Suppl):295-315

3. Labrie F. et al., Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate. 1999 Feb 1;38(2):83-91.

4. Lu-Yao G. et al., Population-based study of long term survival in patients with clinically localized cancer. The Lancet 1997; 349:906-910

5. Catalona WJ, et al Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994 May;151(5):1283-90.

6. Ohori M, et al Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995 Nov; 154(5):1818-24.

7. Scardino PT. Early detection of prostate cancer. Urol Clin North Am. 1989 Nov; 16(4):635-55. Review.

8. Villers A, et al [Prostate cancer screening (III): risk factors, natural history, course without treatment. Characteristics of detected cancers]. Prog Urol. 1997 Sep;7(4):655-61. Review. French.

9. Sakr WA, et al The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 1993 Aug;150(2 Pt 1):379-85.

10. Smith DS, et al Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA. 1996 Oct 23-30;276(16):1309-15.

11. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. British Journal of Urology 79: 235-246, 1997

12. Roberts RO, et al., Decline in Prostate Cancer Mortality from 1980 to 1997, and an update on Incidence Trends in Olmsted County, Minnesota. The Journal of Urology; Vol. 161, 529-533, 1999.

13. Brasso K et al., Mortality of Patients with Clinically Localised Prostate Cancer Treated with Observation for 10 years or longer. The Journal of Urology; Vol. 161, 524-528, 1999.

14. Hankey BF, et al. Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999 Jun 16;91(12):1017-24.

15. Post PN, et al. Increased risk of fatal prostate cancer may explain the rise in mortality in The Netherlands.Int J Epidemiol.1999 Jun;28(3):403-8.

16. Pearson JD et al., Natural history of changes in prostate-specific antigen in early stage prostate cancer. J Urol. 1994 Nov;152(5 Pt 2): 1743-8

17. Carter HB, et al., Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology. 1997 Mar;49(3):379-84)

LINKS will open in a new browser window